drugset / Trial / NCT00967226

Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas

NCT00967226 ↗

Phase 2 Terminated 19 enrolled Nancy Bauman
RandomizedParallel-groupSingle-blindTreatment

Summary

Hemangiomas are relatively common lesions in infants. Most go away spontaneously after one year of life and do not need treatment. Others require treatment because they cause significant symptoms such as pain, or difficulty with breathing, eating or ambulating. Steroids have classically been used to treat hemangiomas and help to shrink them in 1/3 - 2/3 of patients. Unfortunately, steroids have many side effects in babies so physicians have sought other ways to treat them. Recently, the use of propranolol, a heart medication, was serendipitously found to reduce the size of hemangiomas. It appears to have many fewer side effects than steroids but it is not yet known if it works as well as steroids. This study seeks to compare the effect and the side effects of propranolol versus steroids for treating hemangiomas that cause symptoms in infants.

Timeline

Start
2009-07
Primary completion
2013-01
Completion
2014-12

Outcome

Missed primary endpoint

Stopped: “Serious adverse events with prednisolone, primarily temporary growth retardation, \<5th percentile.”

registry analysis (superiority or other test); Propranolol vs Prednisolone; p = 0.77; Mean Difference (Net) 0.06; t-test, 2 sided NCT00967226 ↗

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prednisolone Other / unclassified 1 mg/kg Oral
Subject Propranolol Small molecule 0.5 mg/kg Oral

Indications